Anove-logoAnove-logoExplAIn
KaartenAI-koplopers
Terug naar directory

Visiopharm Insight

door Visiopharm

AI Application
Laag vertrouwen

Insight is Visiopharm's line of IVDR-certified image-analysis apps (APPs) for diagnostic pathology, used by pathologists in hospital laboratories on digitised slides. The vendor lists CE-IVD APPs for ER, PR, Ki-67 and HER2 in breast cancer, PD-L1 in non-small-cell lung cancer, a hot-spot tool, and an AI app that detects metastases in H&E-stained lymph nodes from breast and colorectal adenocarcinoma, marks them as high, medium or low probability, measures the largest metastasis and sorts slides so those with findings are reviewed first. The vendor says the APPs analyse the whole slide without manual interaction, so results are ready for the pathologist's review, and show how close a score is to clinical cut-offs; the pathologist makes the diagnosis. Insight runs on the web, on-premise or hybrid and integrates with Sectra, Philips, Proscia, PathAI, Fujifilm and other image-management systems. Visiopharm separately sells Qualitopix, a research-use web service that uses AI to measure immunohistochemistry staining intensity for quality control.

Bezoek website

Transparantiescore

Gewogen over vier pijlers · bijgewerkt October 20, 2026

Totaalscore
27% gewogen
ABCDF
Model
—
Nog niet beoordeeld
Infrastructuur
—
Nog niet beoordeeld

Functionaliteiten

Lymph Node Metastasis Detection
Biomarker Quantification
Her2 Scoring
Ki67 Scoring
Pd L1 Scoring
Slide Prioritisation

Leveranciersinformatie

Volledige informatie over de leverancier/provider van deze AI-applicatie

VisiopharmBekijk alle producten →
Visiopharm A/S(Handelsnaam: Visiopharm)
Contactinformatie
visiopharm.com
Geregistreerd adres
Agern Allé 24, Hørsholm, Capital Region of Denmark, 2970, DK

Leveranciersinformatie volgens de EU AI Act

Verificatiestatus:
Unverified
Visiopharm A/S(Handelsnaam: Visiopharm)
Agern Allé 24, Hørsholm, Capital Region of Denmark, 2970, DK
Nalevingsdocumenten
CE-markering: Certified
Aangemelde instantie: BSI Group The Netherlands B.V.(Cert.: IVDR 742024)
Visiopharm says its CE-IVD APPs are for in vitro diagnostic use in the EU and UK and are not for sale in the USA, and its site-wide disclaimer reads 'Unless otherwise stated all products are Research Use Only, not for use in diagnostic procedures' (https://visiopharm.com/diagnostics-pathology-image-analysis-software/, read 2026-10-20). It says the Metastasis Detection app is 'optimized for maximum sensitivity' (https://visiopharm.com/app-center/app/metastasis-detection-ai/, read 2026-10-20). No contraindications are published.
Naleving & risico

Krijg inzicht in risico's door beoordelingen uit te voeren op deze AI-applicatie.

Werk je bij Visiopharm? Claim deze vermelding om de gegevens te corrigeren of aan te vullen.

Toegevoegd: October 20, 2026
Bijgewerkt: October 20, 2026

Klaar om AI-applicaties te beheren?

Volg, beoordeel en beheer je AI-applicaties met Anove.

Anove-logoAnove-logoAnove International B.V.

We helpen organisaties AI-applicaties op een verantwoorde manier te ontdekken en beheren. Uw betrouwbare bron voor AI-governance en compliance.

Snelle links

  • Directory bekijken
  • FAQ
  • AI-kaarten per sector
  • Inloggen

Bronnen

  • Documentatie
  • Status
  • Anove.ai

Voorwaarden

  • Privacybeleid
  • Algemene voorwaarden
  • Responsible disclosure
  • AI-juridische kennisgeving
  • Beveiligingsbeleid

© 2026 Anove International B.V. Alle rechten voorbehouden.